Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Additional positive data reported for Cell Pathways' exisulind

Oct. 28, 1999

First macrolide LHRH antagonists patented by Abbott

Oct. 28, 1999

New distamycin derivatives developed at Pharmacia & Upjohn for cancer Rx

Oct. 28, 1999

Dramatic results described for STI-571 in CML patients

Oct. 27, 1999

Second-generation virus from Calydon begins clinical testing in prostate cancer

Oct. 27, 1999

Antisense oligonucleotides that modulate human HER-2 expression patented

Oct. 27, 1999

Polyamine derivatives designed at U. of Florida for reduced toxicity

Oct. 26, 1999

Novel oncological compounds acting as antagonists of protein-carbohydrate binding

Oct. 26, 1999

New antitumor diterpenes discovered in China

Oct. 26, 1999

U. of Minnesota designs anticancer, antiviral phosphoramidated nucleosides

Oct. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...